Munir Rababah,
Hans Worthmann,
Milani Deb,
Anita B Tryc,
Yue Tao Ma, Omnia M El Bendary,
Hartmut Hecker,
Annemarie Goldbecker,
Meike Heeren,
Korbinian Brand,
Karin Weissenborn,
Ralf Lichtinghagen
[show abstract]
[hide abstract]
ABSTRACT: Matrix metalloproteinase-9 (MMP-9) represents a promising marker for acute stroke management. In clinical studies MMP-9 has been quantified by ELISA using differing protocols. We aimed to establish a valid protocol by evaluation of preanalytics.
Blood from stroke patients (n=28) and healthy controls (n=28) was drawn into tubes containing different anticoagulants (EDTA, citrate, lithium-heparin (heparin) and heparin with proteinase inhibitors) and processed after 0, 60 and 240 min. MMP-9 plasma protein and mRNA from mononuclear leukocytes were determined.
In regard to anticoagulants used, samples showed different MMP-9 protein baseline values and kinetics. Stable MMP-9 protein concentrations were only measured from EDTA samples. Particularly in samples with proteinase inhibitors protein and mRNA concentrations increased over time. Kinetics did not differ between patients and controls.
Preanalytics plays a key role for determination of MMP-9. EDTA seems to be a valid anticoagulant for MMP-9 protein measurement.
Clinical biochemistry 02/2012; 45(6):483-9. · 2.02 Impact Factor
